ADD Star Cement

Strong quarter; capacity augmentation to drive volumes

Cement > Result Update > **February 8, 2024**

Star Cement's consolidated EBITDA increased 37% YoY/51% QoQ to Rs1.5bn in Q3FY24 which was 15% above Consensus estimate. EBITDA/t stood at Rs1,538 (18-quarter high). Volume grew 7% YoY/ 8% QoQ to 0.9mt (in line with estimates). Realizations improved 3% QoQ to Rs6,736/t on account of price increases in the north-eastern region (NER). While, Q4FY24 has started on a tepid note, the management expects the volume trajectory to accelerate in FY25 owing to commissioning of new capacities (targets 18% YoY growth in FY25). Star has embarked on a journey to strengthen its market share in NER to over 30% (currently at 25%) by FY26-27, by more than doubling its capacity. Factoring-in the Q3 performance, we raise our EBITDA by 4-7% for FY25-26E and maintain our ADD rating on the stock, with revised Dec-24E TP to Rs210/share (based on 10x EV/EBITDA).

Star Comonti	Einoncial	Spanchat	(Concolidated)	4
Star Cement:	Filidifcial	SHADSHOL	(Consolidated)	

Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E							
Revenue	22,218	27,048	28,667	33,660	39,100							
EBITDA	3,453	4,684	5,768	7,040	8,340							
Adj. PAT	2,468	2,476	3,122	4,047	4,858							
Adj. EPS (Rs)	6.1	6.1	8.2	10.0	12.0							
EBITDA margin (%)	15.5	17.3	20.1	20.9	21.3							
EBITDA growth (%)	3.8	35.7	23.1	22.1	18.5							
Adj. EPS growth (%)	34.6	0.3	33.9	22.1	20.0							
RoE (%)	11.6	10.8	12.1	13.7	14.3							
RoIC (%)	15.1	15.0	16.1	15.1	15.3							
P/E (x)	32.1	32.0	25.4	19.6	16.3							
EV/EBITDA (x)	21.4	16.0	13.9	11.3	9.2							
P/B (x)	3.7	3.3	2.9	2.5	2.2							
FCFF yield (%)	3.0	(2.6)	(7.0)	0.6	3.3							

Source: Company, Emkay Research

Result Summary

Revenue grew 5% YoY (11% QoQ) to Rs6.2bn. Overall volume grew 7% YoY, whereas volume in NER increased 11% YoY (better than industry volume growth of 3% YoY). Total cost/t dropped, by Rs234 QoQ to Rs5,198, mainly on account of reduction in RM+P&F cost by Rs123/t QoQ (fuel cost fell to Rs1.75/Kcal vs. Rs1.9 in Q3FY24). Realizations improved by Rs204/t to Rs6,522/t. Subsequently, Company recorded one of its highest EBITDA/t numbers, at Rs1,538 (up Rs438/t QoQ). Company is on track to increase its clinker and grinding capacities to 5.8mt and 9.7mt, respectively, and has already spent ~Rs12bn, as of Dec-23. The new grinding unit in Guwahati will be eligible for capital subsidy, i.e. 200% of capex. Company will accrue Rs1.5-1.6bn worth of incentives over the next 5-7 years. Star maintains its healthy cash reserves, of Rs1.2bn as of Dec-23. Despite the ongoing capex, we expect leverage to stay low over FY25-26E.

What we like: Better than expected profitability

What we do not like: Slight delay in commissioning of the upcoming project

Key Concall Takeaways: i) Star's 2mt GU in Guwahati to be commissioned by Mar-24 (earlier, Dec-23), while its 3mt clinker plant in Meghalaya is expected to be commissioned in Mar-24 (earlier, Feb-24). ii) Post the ongoing expansion, Company targets achieving capacity of 20mt by 2030. Looking to acquire mines in the South and Rajasthan, and setting up a 2.5mt clinker and a corresponding 3.5-4mt GU at capex of around Rs25bn. iii) Company has, till date, spent Rs3.3bn on the Guwahati GU and is expected to incur another Rs550mn in Q4 (project cost down, from Rs4.3bn); similarly, it has spent Rs8.5bn for its clinker unit in Meghalaya and will be spending Rs2bn in Q4 and Rs1bn in Q1FY25. iv) Company expects volumes to grow 7-8% in Q4FY24 (vs. industry growth of 5-6%). v) Currently, the total Assam market is ~65% (7.5-8mt) of NER market (12.5-13mt). Star is at present supplying ~1.8mt in Assam and aims for 20% growth in FY25 to 2.2-2.3mt and to 2.6mt in FY26.



Ticker

TARGET PRICE (Rs): 210

Target Price – 12M	Dec-24
Change in TP (%)	13.3
Current Reco.	ADD
Previous Reco.	ADD
Upside/(Downside) (%)	6.9
CMP (08-Feb-24) (Rs)	196.1

Stock Data

I

(

Stock Butu	Herei
52-week High (Rs)	198
52-week Low (Rs)	103
Shares outstanding (mn)	404.2
Market-cap (Rs bn)	79
Market-cap (USD mn)	955
Net-debt, FY24E (Rs mn)	744
ADTV-3M (mn shares)	1
ADTV-3M (Rs mn)	138.2
ADTV-3M (USD mn)	1.7
Free float (%)	-
Nifty-50	21,718
INR/USD	83.0
Shareholding, Dec-23	
Promoters (%)	66.5
FPIs/MFs (%)	1.1/6.1

Price Performa	Price Performance									
(%)	1M	3M	12M							
Absolute	9.4	19.4	71.9							
Rel. to Nifty	8.3	6.9	41.4							





Dharmesh Shah

dharmesh.shah@emkayglobal.com +91 22 6612 1255

Cheragh Sidhwa

cheragh.sidhwa@emkayglobal.com +91 22 6612 1219

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 05/01/2024 12:58 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAYsGO>Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Quarterly Analysis

Exhibit 1: Actual vs. Estimates (Q3FY24)

(Rs mn)	Actual	Estim	ates	Variati	ion (%)	Comment	
	Actual	Emkay	Consensus	Emkay	Consensus		
Net sales	6,514	6,506	6,495	0.1	0.3		
EBITDA	1,488	1,354	1,297	9.9	14./	EBITDA beat owing to lower than expected input costs	
PAT	735	750	726	(2.0)	1.3		
Volumes (mt)	0.97	0.97		-			
Cement realization (Rs/ton)	6,736	6,728		0.1			
EBITDA/ton (Rs)	1,538	1,400		9.9			

Source: Bloomberg, Emkay Research

Exhibit 2: Quarterly analysis

(Rs mn)	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	YoY (%)	QoQ (%)	9MFY23	9MFY24	YoY (%)
Revenue	6,195	8,300	7,605	5,853	6,514	5.1	11.3	18,790	19,971	6.3
Expenditure	5,111	6,638	6,312	4,867	5,026	(1.7)	3.3	15,768	16,205	2.8
Total RM cost	1,090	1,967	2,003	1,195	1,250	14.7	4.6	4,306	4,448	3.3
Staff cost	486	558	510	571	545	12.1	(4.5)	1,472	1,626	10.5
Other expenditure	3,535	4,113	3,799	3,101	3,231	(8.6)	4.2	9,990	10,131	1.4
EBITDA	1,084	1,662	1,293	986	1,488	37.2	50.9	3,022	3,766	24.6
Depreciation	341	351	318	360	365	7.2	1.4	960	1,043	8.6
EBIT	743	1,311	975	625	1,122	51.0	79.5	2,062	2,723	32.1
Other Income	117	127	87	58	41	(64.8)	(28.4)	393	186	(52.6)
Interest	33	12	22	32	30	(10.2)	(8.7)	85	85	(0.8)
РВТ	828	1,427	1,040	651	1,134	37.0	74.3	2,370	2,824	19.2
Total Tax	299	466	300	244	399	33.4	63.5	855	943	10.3
Adjusted PAT	529	961	739	407	735	39.0	80.8	1,515	1,881	24.2
(Profit)/loss from JVs/Assoc./MI	-	-	-	-	-			-	-	
PAT after MI	529	961	739	407	735	39.0	80.8	1,515	1,881	24.2
Extra ordinary items	-	-	193					-	193	
Reported PAT	529	961	932	407	735	39.0	80.8	1,515	2,074	36.9
Adjusted EPS (Rs)	1.3	2.4	1.8	1.0	1.8	39.0	80.8	3.7	4.7	24.2
(%)	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	YoY (bps)	QoQ (bps)	9MFY23	9MFY24	YoY (bps)
EBITDAM	17.5	20.0	17.0	16.8	22.8	30.5	35.6	16.1	18.9	277
EBITM	12.0	15.8	12.8	10.7	17.2	43.6	61.2	11.0	13.6	266
EBTM	13.4	17.2	13.7	11.1	17.4	30.3	56.6	12.6	14.1	153
PATM	8.5	11.6	9.7	6.9	11.3	32.2	62.4	8.1	9.4	136
Effective Tax rate	36.1	32.6	28.9	37.5	35.2			36.1	33.4	

Source: Company, Emkay Research

Exhibit 3: Quarterly analysis on a per-ton basis

(Rs/ton)	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	YoY (%)	QoQ (%)	9MFY23	9MFY24	YoY (%)
Volumes (mt)	0.91	1.24	1.16	0.90	0.97	6.5	7.9	2.78	3.03	8.9
Blended Realization	6,823	6,720	6,533	6,532	6,736	(1.3)	3.1	6,761	6,598	(2.4)
Raw Material cost	1,201	1,593	1,721	1,334	1,293	7.7	(3.1)	1,549	1,470	(5.1)
Staff cost	536	452	438	638	564	5.3	(11.6)	530	537	1.4
Other expenditure	3,893	3,330	3,264	3,461	3,341	(14.2)	(3.4)	3,595	3,347	(6.9)
Operating cost	5,629	5,375	5,423	5,432	5,198	(7.7)	(4.3)	5,674	5,354	(5.6)
EBITDA	1,194	1,346	1,111	1,100	1,538	28.8	39.8	1,087	1,244	14.4

Source: Company, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 05/01/2024 12:58 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 4: We increase our FY25-26 estimates by 4-7%

	F	Y24E		I	FY25E		FY26E			
(Rs mn)	Old	New	Chg. (%)	Old	New	Chg. (%)	Old	New	Chg. (%)	
Revenue	29,424	28,667	(2.6)	34,380	33,660	(2.1)	39,470	39,100	(0.9)	
EBITDA	5,467	5,768	5.5	6,742	7,040	4.4	7,773	8,340	7.3	
PAT	3,035	3,122	2.9	3,811	4,047	6.2	4,407	4,858	10.2	

Source: Emkay Research

Exhibit 5: We maintain ADD on Star Cement, with TP of Rs210/share, based on Dec-25E EV/E EV/E valuation Dec-25E EBITDA (Rs bn) 8

Dec-24E Target Price (Rs/share)	210
No. of shares (mn)	404
Equity value (Rs bn)	85
Net debt (Dec-24E; Rs bn)	0.4
Enterprise Value (Rs bn)	85
EV/E (x)	10
	Ŭ

Source: Emkay Research

Exhibit 6: Annual analysis

Key Assumptions	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E	FY26E	CAGR	(%)
key Assumptions	F110	F119	F120	F121	F122	F123	F124E	FIZJE	F120E	FY18-23	FY23-26E
Capacity (mt)	4.3	4.3	4.3	5.7	5.7	5.7	7.7	9.7	9.7	5.8	19.4
Volumes (mt)	2.6	2.7	2.9	2.6	3.4	4.0	4.3	5.0	5.7	9.3	12.4
Utilization (%)	60	63	67	46	60	70	56	51	59		
Blended Realization (Rs/ton)	6,243	6,747	6,389	6,500	6,523	6,735	6,596	6,735	6,863	1.5	0.6
EBITDA/ton (Rs)	2,026	1,660	1,369	1,258	1,014	1,167	1,328	1,410	1,465	(10.4)	7.9
P&L (Rs bn)											
Revenue	16	18	18	17	22	27	29	34	39	10.9	13.1
EBITDA	5	4	4	3	3	5	6	7	8	(2.1)	21.2
Adj. Net Profit	3	3	3	3	2	2	3	4	5	(4.4)	25.2
Balance Sheet (Rs bn)											
Equity	15	17	19	21	22	24	27	32	36		
Net Debt	4	(1)	(3)	(5)	(5)	(5)	1	0	(2)		
Cash Flow (Rs bn)											
OCF before NWC change	5	4	3	2	3	5	4	5	6		
Change in NWC	0	3	1	1	1	(0)	(0)	(0)	(0)		
Capex	(0)	(1)	(2)	(1)	(2)	(6)	(10)	(5)	(4)		
FCF	4	6	2	2	2	(2)	(6)	0	2		
Return ratios (%)											
RoE	22.9	18.7	15.9	12.8	11.6	10.8	12.1	13.7	14.3		
RoCE	17.7	16.3	15.4	12.8	12.2	11.0	11.2	12.4	13.3		
RoIC	18.4	17.9	18.0	15.8	15.2	15.1	16.5	15.1	15.4		
Valuations (x)											
PER							25.4	19.6	16.3		
EV/EBITDA							13.0	11.4	9.5		
EV/ton (USD)							118	101	100		

Source: Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 05/01/2024 12:58 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.


Exhibit 7: Annual analysis on a per-ton basis

(Rs/ton)	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E	FY26E
Blended realization	6,243	6,747	6,389	6,500	6,523	6,735	6,596	6,735	6,863
% YoY	(0.7)	8.1	(5.3)	1.7	0.3	3.2	(2.0)	2.1	1.9
Raw materials cost	1,176	1,614	1,396	1,525	1,685	1,559	1,426	1,448	1,482
Power & fuel cost	840	956	1,257	1,280	1,225	1,419	1,417	1,409	1,402
Freight cost	1,126	1,341	1,226	1,202	1,255	1,262	1,098	1,120	1,148
Staff cost	417	430	439	497	468	488	505	510	510
Other expenses	690	765	713	743	880	843	826	843	860
Total OpEx	4,249	5,107	5,031	5,247	5,513	5,572	5,272	5,330	5,402
% YoY	(11.8)	20.2	(1.5)	4.3	5.1	1.1	(5.4)	1.1	1.4
Other operating income	32	20	11	5	4	4	4	4	4
Blended EBITDA	2,026	1,660	1,369	1,258	1,014	1,167	1,328	1,410	1,465
% YoY	35.7	(18.1)	(17.5)	(8.1)	(19.4)	15.1	13.8	6.1	3.9

Source: Company, Emkay Research



Exhibit 9: One-year forward EV/EBITDA



Source: Bloomberg, Emkay Research

Source: Bloomberg, Emkay Research

Star Cement: Consolidated Financials and Valuations

Profit & Loss	=	-	-	EVOEE	EVECT
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Revenue	22,218	27,048	28,667	33,660	39,100
Revenue growth (%)	29.2	21.7	6.0	17.4	16.2
EBITDA	3,453	4,684	5,768	7,040	8,340
EBITDA growth (%)	3.8	35.7	23.1	22.1	18.5
Depreciation & Amortization	1,216	1,311	1,411	1,594	1,894
EBIT	2,236	3,373	4,358	5,445	6,446
EBIT growth (%)	(7.8)	50.8	29.2	25.0	18.4
Other operating income	15	16	18	19	21
Other income	334	521	239	322	347
Financial expense	133	97	120	349	289
РВТ	2,437	3,797	4,476	5,418	6,504
Extraordinary items	0	0	193	0	0
Taxes	(31)	1,321	1,354	1,371	1,645
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
Reported PAT	2,468	2,476	3,315	4,047	4,858
PAT growth (%)	31.9	0.3	33.9	22.1	20.0
Adjusted PAT	2,468	2,476	3,122	4,047	4,858
Diluted EPS (Rs)	6.1	6.1	8.2	10.0	12.0
Diluted EPS growth (%)	34.6	0.3	33.9	22.1	20.0
DPS (Rs)	0.0	0.0	0.0	0.0	0.0
Dividend payout (%)	0.0	0.0	0.0	0.0	0.0
EBITDA margin (%)	15.5	17.3	20.1	20.9	21.3
EBIT margin (%)	10.1	12.5	15.2	16.2	16.5
Effective tax rate (%)	(1.3)	34.8	30.3	25.3	25.3
NOPLAT (pre-IndAS)	2,265	2,200	3,039	4,068	4,815
Shares outstanding (mn)	404.2	404.2	404.2	404.2	404.2

Balance Sheet					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	404	404	404	404	404
Reserves & Surplus	21,280	23,760	27,074	31,122	35,980
Net worth	21,684	24,164	27,479	31,526	36,384
Minority interests	0	0	0	0	(
Deferred tax liability (net)	0	0	0	0	(
Total debt	76	305	5,305	5,305	3,305
Total liabilities & equity	21,761	24,469	32,784	36,831	39,689
Net tangible fixed assets	6,669	8,670	18,260	24,665	26,77
Net intangible assets	3	3	3	3	3
Net ROU assets	100	100	100	100	10
Capital WIP	1,045	5,506	4,506	1,506	1,50
Goodwill	0	0	0	0	(
Investments [JV/Associates]	18	0	0	0	(
Cash & equivalents	5,466	4,843	4,562	4,993	5,572
Current assets (ex-cash)	11,742	12,192	12,140	13,532	14,993
Current Liab. & Prov.	5,690	6,845	6,786	7,967	9,255
NWC (ex-cash)	6,052	5,347	5,354	5,565	5,738
Total assets	21,761	24,469	32,784	36,831	39,689
Net debt	(5,389)	(4,538)	744	312	(2,267
Capital employed	21,761	24,469	32,784	36,831	39,689
Invested capital	15,232	14,120	23,716	30,332	32,611
BVPS (Rs)	53.7	59.8	68.0	78.0	90.0
Net Debt/Equity (x)	(0.2)	(0.2)	0.0	0.0	(0.1
Net Debt/EBITDA (x)	(1.6)	(1.0)	0.1	0.0	(0.3
Interest coverage (x)	19.3	40.2	38.1	16.5	23.5
RoCE (%)	12.0	16.8	16.1	16.6	17.8

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
РВТ	2,437	3,797	4,476	5,418	6,504
Others (non-cash items)	(197)	(261)	0	0	0
Taxes paid	(350)	(677)	(1,354)	(1,371)	(1,645)
Change in NWC	1,065	(417)	(7)	(210)	(173)
Operating cash flow	4,170	3,753	4,407	5,459	6,521
Capital expenditure	(1,974)	(5,694)	(10,000)	(5,000)	(4,000)
Acquisition of business	0	0	0	0	0
Interest & dividend income	308	466	239	322	347
Investing cash flow	878	(817)	(9,761)	(4,678)	(3,653)
Equity raised/(repaid)	(1,524)	0	0	0	0
Debt raised/(repaid)	(2)	0	5,000	0	(2,000)
Payment of lease liabilities	(4)	(5)	(10)	0	0
Interest paid	(129)	(97)	(120)	(349)	(289)
Dividend paid (incl tax)	0	0	0	0	0
Others	(102)	197	193	0	0
Financing cash flow	(1,756)	100	5,073	(349)	(2,289)
Net chg in Cash	3,292	3,037	(281)	431	579
OCF	4,170	3,753	4,407	5,459	6,521
Adj. OCF (w/o NWC chg.)	3,106	4,170	4,414	5,669	6,695
FCFF	2,197	(1,941)	(5,593)	459	2,522
FCFE	2,195	(1,941)	(593)	459	522
OCF/EBITDA (%)	120.8	80.1	76.4	77.5	78.2
FCFE/PAT (%)	88.9	(78.4)	(19.0)	11.3	10.7
FCFF/NOPLAT (%)	97.0	(88.3)	(184.0)	11.3	52.4

Source: Company, Emkay Research

Source: Company, Emkay Research

Valuations and key R	atios				
Y/E Mar	FY22	FY23	FY24E	FY25E	FY26E
P/E (x)	32.1	32.0	25.4	19.6	16.3
P/CE(x)	21.5	20.9	17.5	14.0	11.7
P/B (x)	3.7	3.3	2.9	2.5	2.2
EV/Sales (x)	3.3	2.8	2.8	2.4	2.0
EV/EBITDA (x)	21.4	16.0	13.9	11.3	9.2
EV/EBIT(x)	33.0	22.2	18.4	14.6	11.9
EV/IC (x)	4.8	5.3	3.4	2.6	2.4
FCFF yield (%)	3.0	(2.6)	(7.0)	0.6	3.3
FCFE yield (%)	3.0	(2.6)	(0.7)	0.6	0.7
Dividend yield (%)	0.0	0.0	0.0	0.0	0.0
DuPont-RoE split					
Net profit margin (%)	11.1	9.2	10.9	12.0	12.4
Total asset turnover (x)	1.0	1.2	1.0	1.0	1.0
Assets/Equity (x)	1.0	1.0	1.1	1.2	1.1
RoE (%)	11.6	10.8	12.1	13.7	14.3
DuPont-RoIC					
NOPLAT margin (%)	10.2	8.1	10.6	12.1	12.3
IC turnover (x)	1.5	1.8	1.5	1.2	1.2
RoIC (%)	15.1	15.0	16.1	15.1	15.3
Operating metrics					
Core NWC days	99.4	72.2	68.2	60.3	53.6
Total NWC days	99.4	72.2	68.2	60.3	53.6
Fixed asset turnover	1.5	1.6	1.3	1.1	1.0
Opex-to-revenue (%)	58.6	59.5	58.3	57.6	57.1

Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions com use and downloaded at 05/01/2024 12:58 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
05-Jan-24	180	185	Add	Dharmesh Shah
30-Nov-23	165	180	Add	Dharmesh Shah
30-Nov-23	165	180	Add	Dharmesh Shah
10-Nov-23	159	180	Hold	Dharmesh Shah
17-Oct-23	173	165	Hold	Dharmesh Shah
28-Sep-23	153	165	Hold	Dharmesh Shah
18-Sep-23	161	165	Hold	Dharmesh Shah
09-Aug-23	165	165	Hold	Dharmesh Shah
03-Jun-23	141	125	Hold	Dharmesh Shah
22-May-23	127	125	Hold	Dharmesh Shah
04-May-23	123	125	Hold	Dharmesh Shah
27-Mar-23	111	125	Hold	Dharmesh Shah
02-Mar-23	113	125	Hold	Dharmesh Shah
05-Feb-23	112	125	Hold	Dharmesh Shah
03-Feb-23	112	125	Hold	Dharmesh Shah
29-Dec-22	114	105	Hold	Dharmesh Shah
05-Dec-22	106	105	Hold	Dharmesh Shah
05-Nov-22	105	105	Hold	Dharmesh Shah
04-Oct-22	104	105	Hold	Dharmesh Shah
04-Sep-22	94	105	Hold	Dharmesh Shah
03-Aug-22	94	105	Hold	Dharmesh Shah
04-Jul-22	85	90	Hold	Dharmesh Shah
28-Jun-22	85	90	Hold	Dharmesh Shah
18-May-22	91	100	Hold	Dharmesh Shah
16-Mar-22	94	100	Hold	Dharmesh Shah
27-Jan-22	94	120	Buy	Dharmesh Shah
31-Dec-21	95	130	Buy	Dharmesh Shah
02-Dec-21	96	130	Buy	Dharmesh Shah
02-Nov-21	100	130	Buy	Dharmesh Shah
27-Oct-21	101	130	Buy	Dharmesh Shah

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 05/01/2024 12:58 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014, EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information. It is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 05/01/2024 12:58 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGESL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1. the securities recommended in this report as of February 8, 2024
- GFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report З during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of February 8, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the 5. subject company at the end of the month immediately preceding the February 8, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for
- investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkavglobal.com

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 05/01/2024 12:58 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject Company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.